Sygnature to support pneumococcal diseases project

Will provide chemistry services to the University of Leicester

Sygnature Chemical Services, a UK-based provider of discovery chemistry services to the global pharmaceutical industry, has been selected by the University of Leicester to support a Wellcome Trust Seeding Drug Discovery Initiative (SDDI)-funded research programme.

Under the terms of the agreement, the Nottingham-based firm will provide synthetic, medicinal and computational chemistry services to help Leicester University identify new treatments for the neurological handicaps associated with invasive pneumococcal diseases.

‘For the past 18 months, Sygnature has been supplying medicinal chemistry resource and expertise into a Wellcome Trust SDDI-funded project for another UK university,’ said Dr Simon Hirst, chief executive of Sygnature. ‘This has advanced well and Sygnature’s selection for a second Wellcome Trust-funded project is a testament to the successful application of our know-how and expertise in medicinal and computational chemistry. I am confident that Sygnature will be able to make a significant contribution to the University of Leicester’s pneumococcal diseases programme.’

Companies